Oral and intravenous methylprednisolone equally effective for MS relapses
In practice, methylprednisolon (MP) is administered intravenously in MS patients suffering from relapses. In a recent phase-IV clinical trial, however, Spanish scientists show that the drug has the same mode of action when taken orally. This route of administration would be more convenient for patients and has lower costs, the researchers write in Multiple Sclerose Journal. Continue reading